From global vaccines to personalized cancer therapies, mRNA is being considered across several clinical applications, which ultimately creates varying requirements in terms of production scale and ...

— Partnership Combines Sequence Design Expertise with End-to-End GMP Manufacturing to Streamline mRNA Development and Scale-up — BIOVECTRA, a part of Agilent Technologies Inc., and Revolution ...

Stay ahead in the rapidly evolving LNP space with the 4 th LNP Formulation & Process Development Summit—the largest global meeting dedicated purely to LNPs. The official event guide is your must-have ...

RNA vaccines, such as those used against COVID-19, are effective at generating antibody responses. These antibodies are produced through specialized immune structures called germinal centers, but ...

A new class of lipids improve the rates at which lipid nanoparticles (LNPs) successfully deliver RNA therapeutics and gene editing tools, promising to increase their effectiveness of such treatments.

Key presentation unveiled Acuitas’ Next-Generation LNP Advancements, which is designed to enhance potency and safety, expand delivery beyond the liver, and enable broader therapeutic impact Additional ...

Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) and Hokkaido University (Location: Hokkaido ...

Phase 2 IND submission targeted for the second half of 2026- Demonstrating the competitiveness of GC Biopharma's mRNA platform   YONGIN, South Korea, Dec. 22, 2025 /PRNewswire/ -- GC Biopharma (006280 ...

BIOVECTRA, a part of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. today announced a collaboration that grants BIOVECTRA access to Revolution Biomanufacturing's proprietary platforms ...